Ventricular arrhythmias and sudden death in patients taking ibrutinib

Benjamin L. Lampson, Lijian Yu, Robert J. Glynn, Jacqueline C. Barrientos, Eric D. Jacobsen, Versha Banerji, Jeffrey A. Jones, Renata Walewska, Kerry J. Savage, Gregory F. Michaud, Javid J. Moslehi and Jennifer R. Brown

Published e-Letters

Compose eLetter

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
Publication Date - String
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.

Vertical Tabs

Jump to comment:

  • RE: Ibrutinib and short-coupled variant of torsade de pointes
    • Joachim Alexandre, Clinical pharmacology CHU Caen, France
    • Other Contributors:
      • Joe-Elie Salem, Clinical pharmacology
      • Christian Funck-Brentano, Clinical pharmacology
      • Paul Milliez, Cardiology

    We appreciated the letter by Lampson et al. 1 regarding the ventricular arrhythmogenicity of ibrutinib. As pointed out by the authors, ibrutinib was already known to induce atrial fibrillation (AF) but was considered exempt of effect on ventricular repolarization without any impact on QTc interval. Interestingly, the authors described polymorphic ventricular tachycardia including normal QTc interval, without any short-long-short–coupling patterns before the start of episodes, occurring without any underlying cardiac disease. This ECG description corresponds to the short-coupled variant of torsade de pointes first described in 1994 which has the particularity of a short coupling ventricular premature beat initiating ventricular tachycardia 2. Beyond semantics, this distinct form of torsade de pointes has a particular pathophysiology that could help understand ibrutinib arrhythmogenicity. Although the underlying mechanism remains uncertain, it appears that sarcoplasmic reticulum Ca2+ leak plays a major role. Recently, cardiac ryanodine receptor (RyR2) variant with reduced Ca2+ release was associated to short-coupled variant of torsade de pointes 3. It was recently shown that ibrutinib could increase de risk of AF by inhibiting cardiac PI3K-Akt signaling 4. Since cardiac PI3K-Akt signaling was previously linked to the β-adrenergic receptors-cAMP- Calmodulin-dependent protein kinase (CaMKII)-RyR2 pathway to modulate sarcoplasmic reticulum Ca2+ leak 5, it seems reasonable to a...

    Show More
    Conflict of Interest:
    None declared.